Business
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
- Targeted enrollment of 168 RRMS patients achieved in December 2024 - The last patient is expected to complete the trial in the third quarter of 2025 SAN
About this update from Contineum Therapeutics, Inc.
[{"type":"text","content":"\n- Targeted enrollment of 168 RRMS patients achieved in December 2024\n- The last patient is expected to complete the trial in the third quarter of 2025\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nContineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multiple sclerosis (RRMS).\n\n\nThe Phase 2, randomized, double-blind, placebo-controlled, multi-center, proof-of-concept trial of PIPE-307 will assess safety and efficacy in RRMS patients. The trial is designed to measure multiple clinical and imaging endpoints sensitive to changes in remyelination in RRMS. Contineum anticipates that the last patient will complete the PIPE-307 VISTA trial in the third quarter of 2025. More information on this trial can be found at https://clinicaltrials.gov (NCT06083753).\n\n\n“We are pleased to reach this significant milestone for the PIPE-307 VISTA trial ahead of schedule,” said Stephen Huhn, Chief Medical Officer, Contineum Therapeutics. “The trial is designed to show evidence of remyelination as a potentially first-in-class and differentiated therapy for RRMS patients. We believe that PIPE-307 could represent the next evolution in the treatment paradigm for RRMS. We are grateful for the VISTA trial investigators, patients and their families, and we look forward to sharing topline data from this trial.”\n\n\nPIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company.\n\n\nAbout Contineum Therapeutics\n\n\nContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, an...